drugset / Trial / NCT01739023

Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI

NCT01739023 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of autologous human Schwann cells (ahSC) transplantation in subjects with subacute SCI. For humans with subacute SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC. In addition spinal cord cavitation may be reduced, and neural sprouting and plasticity may be enhanced via neurotrophic effects.

Timeline

Start
2012-11
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Human Schwann Cells Cell therapy — Other